Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares of the company’s stock, valued at approximately $4,529,594.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Susanna Gatti High also recently made the following trade(s):
- On Friday, June 21st, Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.01, for a total value of $1,042,842.87.
- On Monday, June 24th, Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.33, for a total value of $359,058.79.
Dyne Therapeutics Price Performance
Dyne Therapeutics stock opened at $36.41 on Friday. Dyne Therapeutics, Inc. has a 1-year low of $6.40 and a 1-year high of $47.45. The business has a fifty day moving average price of $41.28 and a 200-day moving average price of $33.47. The stock has a market capitalization of $3.18 billion, a price-to-earnings ratio of -9.17 and a beta of 1.07.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Algert Global LLC grew its stake in Dyne Therapeutics by 255.1% during the 2nd quarter. Algert Global LLC now owns 97,370 shares of the company’s stock valued at $3,436,000 after purchasing an additional 69,947 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Dyne Therapeutics by 96.2% in the second quarter. The Manufacturers Life Insurance Company now owns 126,244 shares of the company’s stock valued at $4,455,000 after buying an additional 61,902 shares during the last quarter. AQR Capital Management LLC boosted its position in Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after buying an additional 352 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in Dyne Therapeutics in the 2nd quarter worth approximately $3,529,000. Finally, First Light Asset Management LLC raised its position in Dyne Therapeutics by 261.0% during the 2nd quarter. First Light Asset Management LLC now owns 382,433 shares of the company’s stock worth $13,496,000 after buying an additional 276,485 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.
Analyst Upgrades and Downgrades
DYN has been the subject of a number of research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Stifel Nicolaus upped their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Piper Sandler increased their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Guggenheim boosted their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Finally, StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.
Read Our Latest Stock Report on DYN
Dyne Therapeutics Company Profile
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
See Also
- Five stocks we like better than Dyne Therapeutics
- How to Buy Cheap Stocks Step by Step
- 3 Dividend-Yielding Stocks Too Cheap to Pass Up
- What to Know About Investing in Penny Stocks
- Triple Witching: The Market’s Quarterly Rollercoaster
- 3 Monster Growth Stocks to Buy Now
- 4 Stocks Set to Benefit from Recent Interest Rate Cuts
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.